A Phase 2 Randomized, Double-Blind, Placebo- Controlled Study of the Safety and Efficacy of Talactoferrin in Patients With Severe Sepsis*

Alejandro C. Arroliga,Robert A. Balk,Chad M. Cannon,Nathan C. Dean,Phillip Dellinger,Paula Dennen,Juan Figueroa,Eugene Fletcher,Kalpalatha K. Guntupalli,David T. Huang,Mitchell M. Levy,Takkin Lo,Imrana Malik,Benjamin D. Margolis,George M. Matuschak,Laura J. Moore,Gregory J. Moran,Eugene W. Moretti,Peter E. Morris,Edward A. Panacek,Emanual Rivers,Greg Schmidt,Michael G. Seneff,Jay Steingrub,R. Taylor

A Phase 2 Randomized, Double-Blind, Placebo- Controlled Study of the Safety and Efficacy of Talactoferrin in Patients With Severe Sepsis*

2013

Objectives:Lactoferrin is a glycoprotein with anti-infective and anti-inflammatory properties found in secretions and immune cells. Talactoferrin alfa, a recombinant form of human lactoferrin, has similar properties and plays an important role in maintaining the gastrointestinal mucosal barrier inte

Keywords:

Lactoferrin
Intensive care medicine
Septic shock
Immune system
Sepsis
Talactoferrin
Placebo-controlled study
Talactoferrin Alfa
Medicine
Prospective cohort study
severe sepsis

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations